Science & Enterprise subscription

Follow us on Twitter

  • A new enterprise, spun off from Seattle Children’s Research Institute, is creating therapeutics for diseases from e… https://t.co/CvnMEFT0Cm
    about 7 hours ago
  • New post on Science and Enterprise: Start-Up Developing Engineered B-Cell Therapies https://t.co/vMgdwnIXdi #Science #Business
    about 8 hours ago
  • Global drug maker Roche Group is acquiring an experimental antiviral therapy for Covid-19 infections taken as a ora… https://t.co/e2d7m6HG1E
    about 11 hours ago
  • New post on Science and Enterprise: Roche Gains Covid-19 Oral Drug Candidate https://t.co/nh27g6uCwi #Science #Business
    about 11 hours ago
  • The day that America lost $100 billion because of an immigration visa ban https://t.co/OfEx6SFwxA via @BrookingsInst
    about 1 day ago

Please share Science & Enterprise

Start-Up Developing Engineered B-Cell Therapies

Human B-cell

A new enterprise, spun off from Seattle Children’s Research Institute, is creating therapeutics for diseases from engineered B-cells in the immune system. . . . → Read More: Start-Up Developing Engineered B-Cell Therapies

Q3 Venture Funds Inch Up, Early-Stage Deals Drop

Early-stage venture Q3 2020

Venture capital funding rose in the third quarter of 2020, driven in large part by investments in already established companies rather than newer enterprises. . . . → Read More: Q3 Venture Funds Inch Up, Early-Stage Deals Drop

Lilly Gains Neuro Disease Biotech in $1.36B Deal

Nerve cells illustration

Drug maker Eli Lilly and Co. is acquiring Disarm Therapeutics, a biotechnology company developing treatments for neurodegenerative disorders. . . . → Read More: Lilly Gains Neuro Disease Biotech in $1.36B Deal

New Company IDs Drugs Targeting Cancer Cell Networks

Cancer magnified

A start-up company is using artificial intelligence to discover drugs that address the tumor stroma, a cellular network supporting cancerous tumors. . . . → Read More: New Company IDs Drugs Targeting Cancer Cell Networks

Microbiome Therapies Company Unveils, Raises $50M

Microbiome graphic

A new enterprise is underway developing therapeutics targeting bacterial communities in the body, to treat metabolic disorders and cancer. . . . → Read More: Microbiome Therapies Company Unveils, Raises $50M

Heart Disease Biotech Acquired in $13.1B Deal

Wall Street sign

A company developing precision medicine drugs to treat inherited heart disorders was acquired by drug maker Bristol Myers Squibb, or BMS, for $13.1 billion. . . . → Read More: Heart Disease Biotech Acquired in $13.1B Deal

Infographic – Global Climate Technology Hubs

Chart: climate tech hubs

The report also highlights where the investments were made, with the geographic hubs or clusters attracting the most investments, this weekend’s infographic. . . . → Read More: Infographic – Global Climate Technology Hubs

Chip-Based RNA Biotech Raises $60M in Venture Funds

DNA chip graphic

A company developing messenger RNA therapeutics on demand from single-use biochips is raising $60 million in its second venture funding round. . . . → Read More: Chip-Based RNA Biotech Raises $60M in Venture Funds

Cancer Screening Analytics Company Acquired in $8B Deal

Blood sample vials

A company creating a blood test to screen for multiple types of cancer is being acquired by genomics analytics company Illumina for $8 billion in cash and stock. . . . → Read More: Cancer Screening Analytics Company Acquired in $8B Deal

Mental Health Drug Company Raises $127.5M in IPO

NASDAQ share price display

A company developing a drug for depression based on synthesized compounds in hallucinogenic substances is raising $127.5 million in its initial public stock offer. . . . → Read More: Mental Health Drug Company Raises $127.5M in IPO